China’s Center for Drug Evaluation (CDE) is taking steps to rein in the nation’s exploding anticancer drug clinical trials, with a draft document that would require sponsors to conduct randomized controlled studies using best-in-class existing therapies as comparators, where these are available.
When choosing control drugs for such trials, the main focus should be on whether the study products represent the best...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?